Fatty Liver Disease (NAFLD)

What it is

Fatty liver disease (MASLD/NAFLD) is excess fat in the liver not mainly caused by alcohol, and it is now the most common liver disease worldwide. The newer name MASLD stands for metabolic dysfunction-associated steatotic liver disease; NAFLD is the older term, and many clinicians and patients still use it. The key practical fact is that fatty liver is often silent for years, but some people progress from simple fat buildup to inflammation, scarring, cirrhosis, liver failure, or liver cancer.

MASLD is closely linked to metabolic risk factors such as overweight or obesity, type 2 diabetes, high triglycerides, low HDL cholesterol, high blood pressure, and insulin resistance. It is a spectrum rather than a single stage of disease.

Term	What it means
Steatosis	Fat buildup in the liver
MASLD / NAFLD	Steatosis associated with metabolic risk and not explained mainly by alcohol
MASH / NASH	A more severe form with liver cell injury and inflammation
Fibrosis	Scar tissue forming in the liver
Cirrhosis	Advanced scarring that can impair liver function

Many people have no symptoms. When symptoms occur, they may include fatigue, malaise, or discomfort in the upper right abdomen. More advanced disease can cause jaundice, abdominal swelling, leg swelling, itching, easy bruising, or confusion.

In India, MASLD is increasingly relevant because rates of central obesity, type 2 diabetes, and metabolic syndrome are rising even in people who are not markedly overweight by Western standards. South Asians can develop fatty liver at lower body mass index levels than some other populations.

How it works

The liver normally handles fats, sugars, and energy storage. In MASLD, excess calories, insulin resistance, and abnormal fat handling lead to triglyceride accumulation inside liver cells. This is not just a storage problem. In some people, fat buildup is followed by oxidative stress, inflammation, and injury to hepatocytes, which can trigger fibrosis.

Several processes contribute:

1. Insulin resistance increases the flow of fatty acids to the liver.
2. De novo lipogenesis increases, meaning the liver makes more fat from carbohydrate and excess energy.
3. Inflammation and oxidative stress can damage liver cells.
4. Fibrosis pathways activate, causing scar tissue over time.

This is why MASLD is often considered a liver manifestation of broader metabolic disease. The condition is also associated with higher cardiovascular risk, and for many patients, heart disease risk matters as much as liver risk.

Evidence and uses

MASLD is not a benign finding in every patient, but it also does not progress in everyone. The main clinical goals are to identify who has simple steatosis versus who may already have significant fibrosis or MASH.

Current evidence supports these broad points:

• Weight loss helps. In people with excess weight, sustained weight reduction can improve liver fat, liver enzymes, and sometimes inflammation and fibrosis.
• Physical activity helps even without major weight loss. Aerobic exercise and resistance training can reduce liver fat.
• Control of diabetes, lipids, and blood pressure matters. Treating the metabolic drivers is central to care.
• Alcohol intake should be reviewed honestly. Even if alcohol is not the main cause, it can worsen liver injury.

There is no single medicine that is right for every person with MASLD. Some patients with obesity or type 2 diabetes may benefit from medications used for those conditions, including GLP-1 receptor agonists, but treatment choices depend on the whole clinical picture and local approvals. Vitamin E has been studied in selected non-diabetic patients with biopsy-proven NASH, but it is not appropriate for everyone and should not be self-started without medical advice.

Dietary patterns that reduce excess calories and improve insulin sensitivity are commonly advised. These usually emphasize vegetables, pulses, whole grains, nuts, unsweetened dairy where suitable, and less sugar-sweetened beverages, refined starch, and ultra-processed foods. In India, reducing frequent intake of sugary tea or coffee, sweets, sweetened beverages, and large portions of refined rice or maida-based foods may be part of a practical plan, depending on the person’s diet.

Diagnosis / how it's measured

MASLD is usually suspected because of abnormal liver enzymes, fatty liver seen on imaging, or the presence of obesity, diabetes, or metabolic syndrome. Diagnosis is not based on one blood test alone.

Common parts of evaluation include:

Test or tool	What it can show	Limits
ALT, AST, GGT	Liver enzyme abnormalities	Can be normal even when disease is present
Ultrasound	Fatty liver appearance	Less sensitive for mild steatosis
Fibrosis scores such as FIB-4	Estimates risk of advanced fibrosis	Screening tool, not a final diagnosis
Transient elastography (FibroScan)	Liver stiffness and sometimes fat estimate	Availability varies
MRI-based tests	More precise fat measurement	Costly, not routine for everyone
Liver biopsy	Confirms inflammation and fibrosis stage	Invasive, used selectively

Doctors also look for other causes of liver disease, including viral hepatitis, significant alcohol use, medication effects, autoimmune liver disease, and rare metabolic disorders.

A normal ALT does not rule out MASLD or fibrosis. That is an important limitation of routine blood work. Risk stratification often matters more than simply asking whether fat is present.

When to see a clinician

See a clinician if you have fatty liver on an ultrasound, persistently abnormal liver tests, type 2 diabetes, obesity, high triglycerides, or a strong family history of liver disease. You should also seek care if you develop jaundice, abdominal swelling, vomiting blood, black stools, confusion, severe fatigue, or unexplained weight loss, because these can suggest advanced liver disease or another serious condition.

Ask whether you need fibrosis assessment, not just repeat liver enzymes. People with diabetes, metabolic syndrome, or suspected cirrhosis often need closer follow-up. A hepatologist or gastroenterologist may be involved if fibrosis risk is high.

Limitations and open questions

The name change from NAFLD to MASLD reflects a shift toward recognizing metabolic dysfunction as the main driver, but terminology is still evolving in clinics and research. Some studies use older definitions, so comparing results across papers can be difficult.

Another challenge is that many people with fatty liver never develop serious liver disease, while others progress despite modest symptoms and only mild enzyme changes. Better tools are still needed to predict who will develop MASH, advanced fibrosis, cirrhosis, or liver cancer.

Evidence for lifestyle treatment is strong in principle, but long-term adherence is difficult in real life. Evidence for medicines is improving, especially in people with obesity and diabetes, but not every drug that lowers liver fat clearly improves fibrosis or long-term outcomes. Human evidence also varies by population, and more India-specific data are still needed.

Because MASLD is tied to the whole metabolic system, management works best when liver care is combined with diabetes, lipid, blood pressure, sleep, and weight management rather than treated as an isolated liver problem.